FDA: Cutting-Edge Technology Sheds Light on Antibiotic Resistance
Public health agencies around the world are dealing with the growing challenge of bacterial resistance to antibiotics
When your child has a bacterial infection, you take him or her to the doctor, get a prescription for an antibiotic, and, in most cases, all is soon well.
But while antibiotics work for most patients with a bacterial infection, they may not work for all infections. Public health agencies around the world are dealing with the growing challenge of bacterial resistance to antibiotics, which can make these medications ineffective.
The Centers for Disease Control and Prevention (CDC) reports that every year at least 2 million illnesses and 23,000 deaths in the United States are caused by antibiotic-resistant bacteria. The problem is especially serious for patients who have few viable antibiotic options; this can occur with certain types of serious bloodstream infections and with gonorrhea infections, among others.
The CDC says that overuse of antibiotics in both humans and animals helps drive the evolution of resistant bacteria. Why? The bacteria have a natural tendency to mutate and to acquire genes from other bacteria. These changes can enable them to resist the antibiotics and flourish in environments where antibiotics are used. As the resistance genes move between bacteria, the bacteria themselves spread through soil, water, and wildlife. Over time, with continued antibiotic use, the situation worsens.
Resistance Spreading Globally
Scientists are concerned that resistant strains of bacteria could spread globally through travel or trade, including the exchange of foods. To help identify the presence of antibiotic-resistant bacteria as early as possible, and take steps to control their further spread, the Food and Drug Administration (FDA) is using cutting-edge technology called whole genome sequencing (WGS).
A genome is an organism's complete set of genes. In the 20 years since the first bacterial genome was completely sequenced, the science has advanced dramatically. The first bacterial genome sequence was uncovered in 1995 at a cost of several hundred thousand dollars and many months of work. Now it costs around $50 per genome and dozens can be done together overnight.
"For the first time, we can rapidly determine the entire collection of known antibiotic resistance genes in an individual bacterium," said Patrick McDermott, Ph.D., director of FDA's National Antimicrobial Resistance Monitoring System (NARMS). "This is allowing new insights into the nature and magnitude of the resistance threat. And, because the database of resistance genes is growing, due to work by scientists around the globe, we can see what others are finding and quickly ascertain if resistance threats emerging in other countries also are present in the United States."
Whole genome sequencing is also revealing new types of resistance genes in disease-causing bacteria, says McDermott. For example, NARMS data showed a rapid rise in gentamicin resistance in the foodborne bacteria, campylobacter. Gentamicin is an antibiotic used to treat certain serious bacterial infections. WGS analysis showed that the genes causing this resistance are numerous, and most had never been seen before.
Controlling the Problem
McDermott says that surveillance plays a big role in identifying the problem and possible solutions. "You need a monitoring system in place to understand how big the problem of antibiotic resistance is—and whether the situation is improving or getting worse," he said.
To that end, NARMS was established in 1996 as a partnership of state and local public health departments, the FDA, the CDC, and the U.S. Department of Agriculture (USDA). NARMS tests foodborne bacteria from retail meats, food animals, and clinical cases of human illness to see which resistant bacteria are moving through the food supply and to what extent.
Surveillance data can be combined with other public health data to reveal useful information about how resistant infections differ from susceptible infections (infections antibiotics effectively combat). These data are also important to determine how successful the interventions designed to limit the spread of resistance actually are. "The ultimate goal is to preserve the effectiveness of antibiotics for use in both humans and animals," McDermott added.
Detecting Antibiotic Resistance Genes
According to the FDA, WGS has been an important tool in the continuing investigation into the presence in the United States of a gene (mcr-1) that causes resistance to the drug colistin. Colistin is considered a drug of last resort to treat some serious infections.
This gene was first discovered by scientists in China in November 2015, and was later detected in Europe, Canada and elsewhere. In response, NARMS teams looked at the DNA sequence of genes for more than 100,000 individual bacteria in the national database, which includes information from NARMS, FDA's GenomeTrakr National Foodborne Pathogen database, and other sequence data housed at the National Center for Biotechnology Information, part of the National Institutes of Health.
The FDA says that the difficulty in finding resistant organisms, coupled with the fact that the drug is not used in food animals in the U.S. , suggest that colistin resistance poses a low risk to public health in this country. Thus far, the mcr-1 gene has been identified in four people in the U.S. treated for E. coli infections. NARMS will continue to monitor for the mcr-1 gene to watch for any changes in the situation.
The FDA's efforts do not stop at its borders. "Antibiotic resistance is an international challenge," McDermott adds. "We are committed to sharing U.S. data with other countries. This transparency and partnership is indispensable to combating antibiotic resistance globally."